Dividend
View Older Stories View More Recent Stories
-
Pfizer (PFE) Shares Higher Following Boosted Dividend, New Buyback
-
Pfizer Inc. (PFE) Adds $10 Billion to Buyback Plan
-
Pfizer, Inc. (PFE) Raises Quarterly Dividend 10% to $0.22; 4.3% Yield
-
Pfizer Declares A 22-Cent First-Quarter 2012 Dividend
-
Leerink Swann Downgrades Pfizer (PFE) to Market Perform; Major Catalysts Realized
-
Notable Stocks Trading Ex-Dividend Tomorrow 11/09: (BA) (WY) (PFE) (SE)
-
Pfizer Reports Third-Quarter 2011 Results
-
Pfizer, Inc. (PFE) Declares $0.20 Quarterly Dividend; 4.1% Yield
-
Pfizer Declares A 20-Cent Fourth-Quarter 2011 Dividend
-
After-Hours Movers 10/05: (ZUMZ) (CMTL) (GLW) Higher; (RT) (YHOO) (PFE) Lower
-
UPDATE - Barclays Downgraded Pfizer (PFE) to Equalweight; Inferior Revenue Recovery Post 'Patent Cliff' Through 2020
-
Goldman Sachs Adds 13% of the DJIA To its Conviction Buy List In Past Two Days
-
Goldman Sachs Added Pfizer (PFE) to Conviction Buy List, Sees 26% Upside
-
Standpoint Research Upgrades Pfizer (PFE) to Buy
-
Q2 Preview: Divide and Conquer May Not Be Pfizer's (PFE) Best Option; Pipeline Looks Strong
-
Unusual 11 Mid-Day Movers 07/20: (NXST) (NLC) (QPSA) Higher; (RVBD) (ICGN) (FTNT) Lower
-
Morning Movers 07/20: (NLC) (TESS) (QPSA) (IDCC) Higher; (ICGN) (RVBD) (FTNT) (CTRN) Lower
-
Pfizer, Inc. (PFE) Declares $0.20 Quarterly Dividend; 3.9% Yield
-
Barclays on U.S. Major Pharmaceuticals: Pipelines Revived? Making Strides in Oncology, Cardiology, and Virology
-
Barclays on U.S. Major Pharmaceuticals: 1Q11 Preview: Restructuring or New Products - Which Is The Lifeline For Pharma?
-
Canaccord Genuity Morning Coffee on Pfizer (PFE): Selling The Farm?
-
Notable Mergers and Acquisitions of the Day 04/04: (VOD) (PFE)/(KKR) (DCO)/(LB) (EPIC)
-
Standpoint Research Downgrades Pfizer (PFE) to Hold; Valuation Call
-
Hedge Fund Investor Scores Big On Navistar (NAV), What Else Is He Buying?
-
Wells Fargo on Large Cap Pharma: Upgrading To Overweight
-
Wells Fargo Starts Pfizer (PFE) at Outperform; Pipeline At Inflection, Dividend/Share Repo Provide Support
-
Pfizer (PFE) Increases Quarterly Dividend 11.1% to $0.20; Yields 4.7%
-
Top 10 News Items 12/6-12/10: Chinese IPO's On Fire!; S&P Makes A Plethora of Changes to Indices; AGL, Nicor Announce Major Deal In Nat-Gas Sector
-
Morning Movers 11/30: BEZ, ICGN, RVR, BWEN, SGMS, PATH Higher; MCOX, ORCT, ROSG, ABAT, CBAK, BPHX, CMED Lower
-
Q3 Preview: Pfizer (PFE) Chugging Strong Into Earnings; M&A and Pipeline Key Focal Points (MRK, NVS)
-
Barclays Maintains an 'Overweight' on Pfizer (PFE); King Acquisition: Good But Not Great
-
Highlights From PFE's Q2 Conference Call: Continued Growth From Wyeth Deal; Projects FY EPS at Upper End of Range
-
Barclays Maintains an 'Overweight' on Pfizer (PFE); Pipeline Dimming; Capital Allocation Comes Into Focus
-
Deutsche Bank Cuts Price Target on Pfizer (PFE) to $20; Maintains Buy
-
Pfizer (PFE) Declares $0.18 Quarterly Dividend; 5% Yield
-
Soleil Securities Reiterates a 'Buy' Rating on Pfizer (PFE); Under-Valued Pipeline Continues to Progress
-
Top 10 News Items 3/1-3/5: Nonfarm Payrolls Better-Than-Expected, Greece Sells Debt in the Open Market, Ford Surpasses GM as Top US Autoseller
-
Morning Movers 3/3: SWWC, TTPA, NOVL, AMCF, UFPT, ETH Higher; MDVN, VISN, CT, RHB Lower
-
Morning Movers 01/11: PEIX, EPCT, MMR, TUES, KTII Higher; CYCC, LUNA, IOC, ASBC, HOGS Lower
-
Pfizer (PFE) Raises Qtr. Dividend by 12.5% to $0.18, Yielding 3.97%
-
While Attention Is on a Pfizer (PFE) Dividend Raise, Merck (MRK) Could Be Ripe for a Hike Too - Analyst
-
Goldman Sachs Removed Abbott Labs (ABT) From Buy List, Eli Lilly (LLY) From Sell List
-
Standpoint Raised Its FY10 Price Target on Pfizer (PFE) to $24
-
Soleil Securities Reiterates a 'Buy' on Pfizer (PFE); Recent Pullback Provides Opportunity Ahead of Catalysts
-
Analyst Expects Pfizer (PFE) To Raise Its Dividend 15-25%
-
Pfizer (PFE) Declares Qtr. Dividend of $0.16, Yielding 4.19%
-
Top 10 News Items 4/27-5/1: Chrysler to Restructure Under Ch. 11 Bankruptcy Protection; Swine Flu Creates Worldwide Pandemic Fears; US Economy Shrank 6.1% During Q1
-
Highlights From Pfizer's (PFE) Q1 Conference Call: Financing For Wyeth Acquisition In Order; Reaffirms Outlook
-
Pfizer (PFE) Declares Qtr. Dividend of $0.16, Yielding 4.92%
-
Pfizer (PFE) May Sell Off Assets To Gain Antitrust Clearance For The Wyeth (WYE) Deal
